ClinicalTrials.gg
RecruitingNCT05982847Updated Apr 7, 2026

National Blood Pressure Screening in Children to Improve Paediatric Healthcare in South Africa

An observational study in Hypertension, Obesity, Adolescent and Obesity, Childhood, sponsored by North-West University, South Africa. Recruiting at 11 sites in 2 countries. Open to participants aged 5 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by North-West University, South Africa · Observational

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
22,464
Ages
5 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Hypertension with a site in South Africa — 7 open to participants now, 10 under way, 5 of them phase 3. Hypertension · South Africa.

Started
2024
with 3 others
Observational
6 of 49
2 open now
Registered
40th of 49
by date
Lead sponsor
3 of 49
North-West University, South Africa

Among the 49 studies in Hypertension with a site in South Africa, this one is one of 4 that started in 2024, is one of 6 observational ones, and was the 40th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

7 of the 49 studies in Hypertension with a site in South Africa are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 5 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Hypertension with a site in South Africa, or all of them as a file.
02

Study summary

The Childhood Hypertension Consortium of South Africa (CHCSA) was established to foster relationships between the healthcare sector and schools through community engagement and outreach as well as contributing to the decolonization of normative paediatric blood pressure reference values. To date, there has been no nation-wide project in South Africa to determine nationally representative normal blood pressure reference values, nor to estimate the true prevalence of hypertension in the paediatric population of the country. This study will provide critical information on the understanding of blood pressure and hypertension in children, especially of African ancestry. Not only will this effort contribute to the development of the first nationally representative normal reference values of blood pressure but will also benefit healthcare providers in the sector with a clear guideline on the management of high blood pressure in children as developed by experts working with these challenges daily.

Read the detailed description

Rationale: Currently there exist no nationally representative set of normative reference values for blood pressure and anthropometry in South African children, while clinicians rely on European and US reference values. The latter seems inappropriate in the South African setting, especially considering the lack of data available in African ancestry normative data.

Objectives: The investigators aim to development the first nationally representative normal reference values of blood pressure and anthropometry in children, to develop scientific evidence-based hypertension guidelines in the paediatric population of South Africa.

Methods: The target population for this study includes 5 to under 18 years school-aged (all school quintiles) children in South Africa from all provinces in the country selected in a randomized manner and to ensure generalizability.

Population: A sample of 22 464 (81% Black African; 9% Coloured; 8% White and 2% Indian/Asian) will be required to enable computation of reference values for each age and sex across urban, peri-urban and rural settings in all provinces.

Time frame: The study will recruit and collect data over a period of five years.

Expected outcomes: The investigators expect that normative blood pressure in children (ages above 5 and under 18 years) will differ from currently accepted international thresholds. The investigators will engage in the communities to optimise awareness and care of high blood pressure and its comorbidities. Recommendations will be made to the National Department of Health regarding blood pressure measurement/screening for hypertension in children at the local clinic in the Road to Health booklet. The investigators will also develop the first clinical practice guidelines for the management of hypertension in children in South Africa in collaboration with hypertension societies.

03

Conditions studied

  • Hypertension
  • Obesity, Adolescent
  • Obesity, Childhood

Keywords

  • Adiposity
  • Blood Pressure
  • Cardiovascular Diseases
  • Health Knowledge, Attitudes, Practice
  • Lifestyle Factors
04

Who can participate

Ages eligible
5 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The target population for this study includes 5 to under 18 years school-aged children in South Africa from all provinces in the country selected in a randomized manner and to ensure generalizability. All South African public ordinary schools are categorised into five groups, called quintiles, largely for purposes of the allocation of financial resources from government. Quintile one is the lowest socioeconomic quintile, while quintile five is the highest. In addition, lower quintile schools are mostly rural and/or peri-urban. Participants will be drawn from quintile 1-5 schools and those in more remote areas will be reached via mobile fieldwork teams. A sample of 22 464 (81% Black African; 9% Coloured; 8% White and 2% Indian/Asian) will be required to enable computation of reference values for each age and sex across urban and rural settings in all provinces.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All children between ages 5-\<18 years
  • All children with voluntary assent/consent and parent's permission

Exclusion criteria

Exclusion Criteria:

  • circumstances interfere with the participant's ability to give (diminished understanding or comprehension, or any language barriers that may pose potential risk in participation under false expectations)
  • randomly selected children who choose not to participate (lack of assent/consent), even if parent's permission was received,
  • conditions that interfere with a patient's ability to follow study guidelines, e.g., the use of drugs, alcohol or tobacco products
  • ages >18 years or under 5 years
  • Children will be excluded from the analysis for the determination of normative reference values for blood pressure and anthropometry if taking certain concomitant medication(s) that may affect their blood pressure, or any underlying disease e.g., chronic kidney disease, chronic heart disease etc. that may raise blood pressure.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
22,464 participants (estimated)
Patient registry
No

Groups and cohorts

  • Boys

    Diagnostic Test: Blood pressure screening

  • Girls

    Diagnostic Test: Blood pressure screening

Interventions

  • Diagnostic testBlood pressure screening

    Blood pressure and anthropometric measurements will be performed in children and adolescents between ages 5-18 years to develop South African nomograms that will aid in the development of clinical practice guidelines to optimise hypertension care in South Africa youth.

    Also known as: Anthropometric measurements

06

What researchers measure

Primary outcomes

  1. To determine and compute nationally representative normative reference values for blood pressure in children

    To date there are no national normative blood pressure reference values for children in South Africa. Normative values used by clinicians are those extrapolated from studies on blood pressure done in the USA and Europe and these may not be truly representative of normative values of blood pressure in South Africa. This study aims to address this issue, because children can be misdiagnosed for high blood pressure based on the wrong normative values.

    Time frame: Through study completion, an average of 1 year

  2. To determine and compute nationally representative normative reference values for blood pressure in children

    Overweight and obesity classification according to the World Health Organisation percentiles for childhood obesity only include a small sample size from less than five African countries, therefore the underrepresentation of children of African ancestry will be addressed by this study.

    Time frame: Through study completion, an average of 1 year

  3. To develop clinical practice guidelines for the management of childhood hypertension in South Africa

    The findings of this study will help develop clinically relevant guidelines for the management of hypertension in children between 5 and 18 years of age based on local normative values, as well as to improve cost and availability of anti-hypertensive agents for children and adolescents.

    Time frame: Through study completion, an average of 1 year

07

Study locations

4 of 11 sites recruiting
  • Walter Sisulu University
    Mthatha, Eastern Cape, South Africa
    Not yet recruiting
  • Nelson Mandela Metropolitan University
    Port Elizabeth, Eastern Cape, South Africa
    Recruiting
  • University of the Free State
    Bloemfontein, Free State, South Africa
    Recruiting
  • University of the Witwatersrand
    Johannesburg, Gauteng, South Africa
    Recruiting
    • Shane Norris, PhD · Contactshane.norris@wits.ac.za
    • Lisa J Ware, PhD · Contactlisa.ware@wits.ac.za
    • Bhavisha Nagar, MD · Sub investigator
    • Karen Peterson, MD · Sub investigator
    • Innocent Maposa, PhD · Sub investigator
    • Sanushka Naidoo, MD · Sub investigator
    • Stephen Tollman, MD · Sub investigator
    • Xavier Gómez-Olivé, MD · Sub investigator
    • Nilesh Lala, MD · Sub investigator
  • University of KwaZulu-Natal
    Durban, KwaZulu-Natal, South Africa
    Not yet recruiting
  • University of Limpopo
    Polokwane, Limpopo, South Africa
    Not yet recruiting
  • Hypertension in Africa Research Team (HART), North-West University
    Potchefstroom, North West 2531, South Africa
    Recruiting
    • Ruan Kruger, PhD · ContactRuan.Kruger@nwu.ac.za · +27824902342
    • Lebo F Gafane-Matemane, PhD · Sub investigator
  • Red Cross War Memorial Children Hospital
    Cape Town, Western Cape, South Africa
    Not yet recruiting
  • South African Medical Research Council
    Cape Town, Western Cape, South Africa
    Not yet recruiting
  • University of Cape Town
    Cape Town, Western Cape, South Africa
    Not yet recruiting
    • Sandra Mukasa, PhD · Contactsandra.mukasa@uct.ac.za
    • Erika Jones, MD · Contacterika.jones@uct.ac.za
    • Friedrich Thienemann, MD · Sub investigator
    • Landon Myer, MD · Sub investigator
    • Patrick Katoto, PhD · Sub investigator
  • University of Zurich
    Zurich, Switzerland
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The national data will be first collated to develop the nomograms for blood pressure and anthropometric measurements. The data will be made available upon reasonable request from the principal investigator(s) after publication of the nomograms findings.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Nov 2028, 55 months after the start.

Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 55 months is above that.

Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2023
First posted
Aug 9, 2023
StartActual
Apr 1, 2024
Primary completionEst.
Nov 30, 2028
CompletionEst.
Nov 30, 2028
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05982847
Lead sponsor
North-West University, South Africa
Collaborators
Medical Research Council, South Africa, University of Cape Town, University of Limpopo, Walter Sisulu University, University of KwaZulu, Red Cross War Memorial Childrens Hospital, University of Witwatersrand, South Africa, University of Zurich, Groote Schuur Hospital, Nelson Mandela Metropolitan University, Chris Hani Baragwanath Academic Hospital, University of the Free State
Responsible party
Ruan Kruger (Professor, North-West University, South Africa) — Principal investigator
First posted
Aug 9, 2023
Start date
Apr 1, 2024
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Apr 7, 2026

Study contacts

Ruan Kruger, PhD
Contact
ruan.kruger@nwu.ac.za
+27182992904
Lebo F Gafane-Matemane, PhD
Contact
lebo.gafane@nwu.ac.za
+27182992193

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion